The use of transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma: a response to the Cochrane Collaboration review of 2011

J Vasc Interv Radiol. 2011 Dec;22(12):1693-6. doi: 10.1016/j.jvir.2011.09.014. Epub 2011 Oct 27.

Abstract

This commentary is written in response to a recent Cochrane Collaboration review published in March 2011 (1). The authors of this commentary would like to express their concerns over the conclusions of the Cochrane review, which state, "There is no firm evidence to support or refute transarterial chemoembolization (TACE) or transarterial embolization (TAE) for patients with unresectable hepatocellular carcinoma (HCC)."

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Carcinoma, Hepatocellular / drug therapy*
  • Carcinoma, Hepatocellular / mortality
  • Chemoembolization, Therapeutic / adverse effects
  • Chemoembolization, Therapeutic / methods
  • Chemoembolization, Therapeutic / mortality
  • Embolization, Therapeutic / adverse effects
  • Embolization, Therapeutic / methods*
  • Embolization, Therapeutic / mortality
  • Evidence-Based Medicine*
  • Humans
  • Infusions, Intra-Arterial / adverse effects
  • Infusions, Intra-Arterial / methods
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / mortality

Substances

  • Antineoplastic Agents